CRISPR Therapeutics sets sights on gene-editing cures for disease
Jea Yu
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for
NASDAQ:CRSPNASDAQ:VRTXNASDAQ:NTLA